Navigation Links
Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

WORCESTER, Mass.--(BUSINESS WIRE)--Jun 28, 2007 - Biovest International, Inc. (OTCBB: BVTI), a majority owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced on June 27, 2007 blinded interim data from the start of its fast-tracked pivotal Phase 3 clinical trial of BiovaxID(TM) for Non-Hodgkin's lymphoma (NHL) from September 2000 through June 2006. This interim blinded data is the most recent data that has been made available to the Company prior to its latest meeting with the Data Monitoring Committee for the ongoing Phase 3 study. The interim blinded data covers 122 patients who have received either BiovaxID or control vaccine. Randomization was 2:1 in favor of BiovaxID. The blinded data in a Kaplan Meier disease-free survival curve for the per-protocol treatment group in the trial showed that approximately 40% of the evaluable patients in the study remained disease-free from 40 months to almost 70 months.

Dr. Steve Arikian, Biovest Chairman and Chief Executive Officer, stated, "Biovest believes these results are consistent with the expected efficacy of BiovaxID vs. control. Moreover, BiovaxID has the longest Phase 3 follow-up data for patients receiving an active immunotherapy for follicular Non-Hodgkin's Lymphoma of any of the Phase 3 Non-Hodgkin's Lymphoma immunotherapy trials ongoing today. We are greatly encouraged by the blinded interim data presented at the Jeffries Healthcare Conference on June 27th, 2007."

BiovaxID is an anti-cancer vaccine undergoing testing in a Fast-Tracked pivotal Phase 3 clinical trial for a target indication of Non-Hodgkin's Lymphoma. BiovaxID is a personalized, patient-specific vaccine designed to stimulate the patient's own immune system to recognize and destroy residual cancerous B-cells that remain after the patient has undergone chemotherapy. Unlike many other approaches to treating NHL, BiovaxID is designed to target only cancerous B-cells.
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
3. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
4. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
5. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
Post Your Comments:
(Date:5/5/2015)... May 5, 2015  As cannabis prohibition ends one state at a time, more cannabis entrepreneurs are coming up with brilliant ... and the primary reason is lack of funding. ... ... ... ...
(Date:5/5/2015)... 5, 2015  ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ... months ended March 31, 2015 and reaffirmed its revenue, ... 2015. First Quarter 2015 Highlights Include: ... of 72% as compared to $10.9 million for the ... non-GAAP EBITDA of $11.5 million, an increase of 170% as ...
(Date:5/5/2015)... , May 5, 2015  Abaxis, Inc. (NasdaqGS: ABAX ... announced today that Clint Severson , chairman and chief ... Lynch 2015 Health Care Conference on Tuesday, May 12, 2015 ... the Encore at the Wynn in Las Vegas, ... worldwide developer, manufacturer and marketer of portable blood analysis systems ...
Breaking Medicine Technology:Top Ten Ways Cannabis Startups are Getting Funded 2Top Ten Ways Cannabis Startups are Getting Funded 3Top Ten Ways Cannabis Startups are Getting Funded 4ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 2ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 3ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 4ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 5ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 6ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 7ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 8ANI Pharmaceuticals Reports First Quarter 2015 Financial Results 9
... CSL Behring today announced that the U.S. Food and ... License Application (BLA) for a human 4-factor prothrombin complex concentrate ... warfarin) in patients with acute major bleeding. If approved by ... first agent of its kind available in the United States. ...
... 29, 2012 Specialty Silicone Fabricators (SSF), a ... device community, inaugurated its state-of-the-art 102,000 square-foot facility ... efficiency, the facility joins all Paso Robles departments, ... facilities in Tustin, Calif. and Elk Rapids, Mich. ...
Cached Medicine Technology:CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy 2CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy 3Specialty Silicone Fabricators Inaugurates New State-of-the-Art Facility in Paso Robles 2
(Date:5/5/2015)... DC (PRWEB) May 05, 2015 ... Hope Initiative, a new study aimed at determining how ... patients. RG is an international non-profit providing rare disease ... sequencing technology, connections to scientists and researchers, and help ... crowdfunding. , “I am excited to see how crowdfunding ...
(Date:5/5/2015)... On April 8th, 2015, at the famous Avalon ... Durkin Entertainment’s “RockNRolla” EcoLuxe Lounge, a daylong event organized ... placement in TV and film. , A gathering ... sound and socially conscious products and services, the EcoLuxe ... appearances at various awards ceremonies and festivals each year, ...
(Date:5/5/2015)... RF Technologies®, a leading provider of personal ... Management Solution with Voice Alarms. The ST750 will play ... to wait for assistance when it detects them starting ... 16 different melodies or tones or silent alerting, by ... Code Alert®. , For 28 years, Sensatec Fall ...
(Date:5/5/2015)... 2015 In the upbeat Moms Helping Moms ... moms to support each other. Parenting is a tough ... makes it so much easier. Mothers talk about how ... less alone and help them realize there’s no perfect parent; ... who are clearly dear friends share that it's just that, ...
(Date:5/5/2015)... AR (PRWEB) May 05, 2015 ... is collaborating with American Eagle Outfitters on a ... enhance natural beauty. , For the debut ... with Aerie by American Eagle ; the ... brand's body-image campaign, called "Aerie REAL," uses models ...
Breaking Medicine News(10 mins):Health News:Rare Genomics Institute to Study Impact of Crowdfunding on Rare Diseases 2Health News:Choices Recovery Mishawaka Talks About Overcoming Adversity with Actor Matthew Ziff at the “RockNRolla Movie Awards” EcoLuxe Lounge 2Health News:RF Technologies® Releases Sensatec® ST750 Voice Alarm for Fall Management 2Health News:RF Technologies® Releases Sensatec® ST750 Voice Alarm for Fall Management 3Health News:Just In Time For Mother’s Day, Healthy Birth Day Releases Video Titled “Moms Helping Moms” Encouraging Mothers To Band Together 2Health News:BLKBOXLabs Finds Real Beauty in Beauty For Real and American Eagle Outfitters’ Aerie-Branded Beauty Line 2Health News:BLKBOXLabs Finds Real Beauty in Beauty For Real and American Eagle Outfitters’ Aerie-Branded Beauty Line 3
... say that breast-feeding can negate the risks of breast cancer ... the age of 25. ,The findings of ... April 16 at the 2007 annual meeting of the American ... ,"Breastfeeding may have a protective effect that negates the ...
... increasingly viewing cured meats with caution. One reason is the ... According to a recent study, the nitrites ... fixative) could well be setting the lungs on a journey ... , The research led by Dr. Rui ...
... to Irish researchers, a smoking ban which began March 2004, ... drastic cut //in air pollution, the health of bar workers ... researchers gave an 83 percent reduction in air pollution and ... the report, which was published in the American Journal of ...
... simply no effect on arthritis, yet another study says. It ... analysis of 20 studies. // ,"We do not have ... on patients' pain," says author Peter Jüni, head of clinical ... ,The paper comes a little more than a ...
... in multiple sclerosis (MS) has been found to also reduce ... one of the most common and debilitating symptoms of MS. ... of Neurology?, the scientific journal of the American Academy of ... the AFFIRM and SENTINEL studies, which involved 2,138 men and ...
... beyond standard monitoring and testing schedules// ,Infection ... Hopkins Hospital have ordered testing for the two ... to its pediatric intensive care unit. ... methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) ...
Cached Medicine News:Health News:Breastfeeding Keeps Breast Cancer At Bay- For Older Mothers 2Health News:Hotdogs And Co.-The Long And Short Of It 2Health News:Ireland’s Smoke Ban Seems To Do The Tric 2Health News:Chondroitin may Not Have Any Beneficial Effect on Arthritis, New Study Says 2Health News:Chondroitin may Not Have Any Beneficial Effect on Arthritis, New Study Says 3Health News:MS Drug Helps Reduce Vision Loss 2Health News:Johns Hopkins Begins Aggressive Screening for 'superbugs' in Children 2Health News:Johns Hopkins Begins Aggressive Screening for 'superbugs' in Children 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: